上海
*僅供醫學專業人士閱讀參考
*以下內容僅供醫療衛生專業人士瀏覽。
精彩資訊等你來
參考文獻：
[1].Zhang J, Dong Q , Wang Y,et al. Tyrosine kinase inhibitor (TKl) plus PD-1 blockade in TKl-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Results of a multicenter,phase 2 trial (TRAP).2025 #6002.
[2].Zhang W, Zhang Z, Lou S, et al. Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study. Front Oncol. 2022 Aug 31:12:929342.
[3].Li J, Qin S, Xu RH, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486-2496.
[4].Xu R , Qin S, Guo W, et al. Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial. Future Oncol. 2021 Apr;17(11):1339-1350.
[5].Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41-53.
NP-AYT-25N389-Valid Until-2027-May
本資料由和黃醫藥提供支持
本資料旨在促進醫藥信息的溝通和交流，而非廣告宣傳。本資料內容不能以任何方式取代專業的醫療指導，也不應被視為診療建議。若您想了解更多有關疾病知識的信息，請咨詢醫療衛生專業人士。
* 此文僅用于向醫學人士提供科學信息，不代表本平臺觀點
特別聲明：以上內容(如有圖片或視頻亦包括在內)為自媒體平臺“網易號”用戶上傳并發布，本平臺僅提供信息存儲服務。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
